Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer
{{output}}
Background: Oncogenic BRAF mutations affect ~4% of non-small cell lung cancer (NSCLC). Class I mutations (i.e., V600) are typically responsive to BRAF/MEK inhibitors, while non-Class I are often resistant. The role of immune chec... ...
